SCHEMBL6163354

SCHEMBL6163354

CCC1=C(OS(=O)(=O)C(F)(F)F)CCC1

nearest known ligand 0.35

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.34
DRD3 P35462 8/20 0.34
DRD1 P21728 5/20 0.34
DRD4 P21917 5/20 0.34
DRD5 P21918 5/20 0.34
HTR1D P28221 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12354193 0.97 DRD2 (0.34) DRD2DRD3DRD1DRD4DRD5
SCHEMBL19141072 0.86
SCHEMBL28881160 0.84 DRD2 (0.32) DRD2DRD3DRD1DRD4DRD5
SCHEMBL17395579 0.83
SCHEMBL8388405 0.81 RXRA (0.30)
SCHEMBL5668749 0.81
SCHEMBL7384939 0.78 DRD2 (0.31) DRD2DRD3DRD1DRD4DRD5
SCHEMBL12616336 0.78 HTR2C (0.33) DRD2DRD3HTR1D
SCHEMBL25317898 0.74 DRD2 (0.32) DRD2DRD3DRD1DRD4DRD5
SCHEMBL2754407 0.74 DRD2 (0.31) DRD2DRD3DRD1DRD4DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 EP disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO disclosed